CZ289629B6 - 2,4-Disulfonyl-alfa-fenyl-terc.butylnitron, jeho soli, farmaceutická kompozice s jeho obsahem a pouľití - Google Patents
2,4-Disulfonyl-alfa-fenyl-terc.butylnitron, jeho soli, farmaceutická kompozice s jeho obsahem a pouľití Download PDFInfo
- Publication number
- CZ289629B6 CZ289629B6 CZ19961775A CZ177596A CZ289629B6 CZ 289629 B6 CZ289629 B6 CZ 289629B6 CZ 19961775 A CZ19961775 A CZ 19961775A CZ 177596 A CZ177596 A CZ 177596A CZ 289629 B6 CZ289629 B6 CZ 289629B6
- Authority
- CZ
- Czechia
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- compound
- tert
- disulfonyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 title description 2
- JYIYPKOJFKMEKS-UHFFFAOYSA-N n-(2,2-dimethyl-1-phenylpropylidene)hydroxylamine Chemical compound CC(C)(C)C(=NO)C1=CC=CC=C1 JYIYPKOJFKMEKS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- 230000000694 effects Effects 0.000 claims abstract description 34
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 17
- 230000000750 progressive effect Effects 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000001990 intravenous administration Methods 0.000 claims abstract description 10
- 208000006011 Stroke Diseases 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 14
- SRHWORQGHZESJE-UHFFFAOYSA-N N-[1-(4,6-disulfonylcyclohex-2-en-1-yl)-2,2-dimethylpropylidene]hydroxylamine Chemical compound CC(C)(C)C(=NO)C1C=CC(CC1=S(=O)=O)=S(=O)=O SRHWORQGHZESJE-UHFFFAOYSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000004792 oxidative damage Effects 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 150000001450 anions Chemical class 0.000 claims description 8
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 abstract description 10
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 229940009456 adriamycin Drugs 0.000 description 17
- 208000028867 ischemia Diseases 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000699694 Gerbillinae Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 231100000225 lethality Toxicity 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- AIMREYQYBFBEGQ-UHFFFAOYSA-N 2-methyl-2-nitropropane Chemical compound CC(C)(C)[N+]([O-])=O AIMREYQYBFBEGQ-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- XWESXZZECGOXDQ-UHFFFAOYSA-N n-tert-butylhydroxylamine Chemical compound CC(C)(C)NO XWESXZZECGOXDQ-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- SYZMDSPSQLBUNT-UHFFFAOYSA-N CC(C)(C)[N+]([O-])=CC1C=CC(=S(=O)=O)CC1=S(=O)=O Chemical compound CC(C)(C)[N+]([O-])=CC1C=CC(=S(=O)=O)CC1=S(=O)=O SYZMDSPSQLBUNT-UHFFFAOYSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102000005396 glutamine synthetase Human genes 0.000 description 4
- 108020002326 glutamine synthetase Proteins 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZTHFMKBWGPYDGL-UHFFFAOYSA-N 4-(C-tert-butyl-N-hydroxycarbonimidoyl)phenol Chemical compound OC1=CC=C(C=C1)C(C(C)(C)C)=NO ZTHFMKBWGPYDGL-UHFFFAOYSA-N 0.000 description 3
- PQYVGRGYAZDHFY-UHFFFAOYSA-N 4-formylbenzene-1,3-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(C=O)C(S(O)(=O)=O)=C1 PQYVGRGYAZDHFY-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- -1 nitron compound Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000003134 recirculating effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical compound C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 description 2
- LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 206010048964 Carotid artery occlusion Diseases 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 150000003869 acetamides Chemical class 0.000 description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000006318 protein oxidation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 239000004246 zinc acetate Substances 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- NKHUJIASZOUKRQ-UHFFFAOYSA-N 4-(C-tert-butyl-N-hydroxycarbonimidoyl)benzoic acid Chemical compound CC(C)(C)C(=NO)C1=CC=C(C(O)=O)C=C1 NKHUJIASZOUKRQ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910000761 Aluminium amalgam Inorganic materials 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- XNIXUMIGZNCVNG-UHFFFAOYSA-N CC(C)(C)[N+](=O)[O-].[N+](=O)(OC(C)(C)C)[O-] Chemical compound CC(C)(C)[N+](=O)[O-].[N+](=O)(OC(C)(C)C)[O-] XNIXUMIGZNCVNG-UHFFFAOYSA-N 0.000 description 1
- WAFUGZAXAQRWNJ-UHFFFAOYSA-N CC(C)(C=NO)C(O)(O)O Chemical compound CC(C)(C=NO)C(O)(O)O WAFUGZAXAQRWNJ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- HKGNLINPEINUHW-UHFFFAOYSA-N N-tert-butyl-1-(6-sulfonylcyclohexa-2,4-dien-1-yl)methanimine oxide Chemical compound CC(C)(C)[N+](=CC1C=CC=CC1=S(=O)=O)[O-] HKGNLINPEINUHW-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- YDCLLEPZALDOEC-UHFFFAOYSA-N OCCCCC(C1=CC=CC=C1)=NO Chemical compound OCCCCC(C1=CC=CC=C1)=NO YDCLLEPZALDOEC-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000776474 Patescibacteria group Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PITQLPMGJWCDRA-XYOKQWHBSA-N n-tert-butyl-1-(4-nitrophenyl)methanimine oxide Chemical compound CC(C)(C)[N+](\[O-])=C/C1=CC=C([N+]([O-])=O)C=C1 PITQLPMGJWCDRA-XYOKQWHBSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- IPCXNCATNBAPKW-UHFFFAOYSA-N zinc;hydrate Chemical compound O.[Zn] IPCXNCATNBAPKW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/173,579 US5488145A (en) | 1993-12-23 | 1993-12-23 | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ177596A3 CZ177596A3 (en) | 1996-12-11 |
| CZ289629B6 true CZ289629B6 (cs) | 2002-03-13 |
Family
ID=22632663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ19961775A CZ289629B6 (cs) | 1993-12-23 | 1994-12-22 | 2,4-Disulfonyl-alfa-fenyl-terc.butylnitron, jeho soli, farmaceutická kompozice s jeho obsahem a pouľití |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US5488145A (https=) |
| EP (1) | EP0736004B1 (https=) |
| JP (3) | JP3412821B2 (https=) |
| KR (1) | KR100370522B1 (https=) |
| CN (1) | CN1070176C (https=) |
| AT (1) | ATE192736T1 (https=) |
| AU (1) | AU679835B2 (https=) |
| BR (2) | BR9408378A (https=) |
| CA (1) | CA2179521C (https=) |
| CZ (1) | CZ289629B6 (https=) |
| DE (1) | DE69424441T2 (https=) |
| DK (1) | DK0736004T3 (https=) |
| ES (1) | ES2145264T3 (https=) |
| FI (1) | FI111718B (https=) |
| GR (1) | GR3034134T3 (https=) |
| HR (1) | HRP950358B1 (https=) |
| HU (1) | HU221167B1 (https=) |
| MY (1) | MY114178A (https=) |
| NO (1) | NO306457B1 (https=) |
| NZ (1) | NZ279025A (https=) |
| PL (1) | PL185189B1 (https=) |
| PT (1) | PT736004E (https=) |
| RU (1) | RU2159231C2 (https=) |
| SG (1) | SG64903A1 (https=) |
| SK (1) | SK282403B6 (https=) |
| TW (1) | TW299315B (https=) |
| UA (1) | UA45964C2 (https=) |
| WO (1) | WO1995017876A2 (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723502A (en) * | 1985-07-18 | 1998-03-03 | Proctor; Peter H. | Topical spin trap composition and method |
| CA2069961C (en) * | 1989-10-17 | 2000-05-02 | John M. Carney | Method and compositions for inhibition of disorders associated with oxidative damage |
| US5622994A (en) * | 1989-10-17 | 1997-04-22 | Oklahoma Medical Research Foundation | Spin trapping pharmaceutical compositions and methods for use thereof |
| US20050107366A1 (en) * | 1991-06-18 | 2005-05-19 | Carney John M. | Spin trapping pharmaceutical compositions and methods for use thereof |
| US6002001A (en) * | 1991-06-18 | 1999-12-14 | Oklahoma Medical Research Foundation | Spin trapping pharmaceutical compositions and methods for use thereof |
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| DK1288203T3 (da) * | 1995-09-11 | 2005-07-11 | Aventis Pharma Inc | Cykliske nitroner og farmaceutiske præparater, der indeholder dem |
| CA2235765C (en) * | 1995-11-17 | 2006-04-04 | David A. Becker | Azulenyl nitrone spin trapping agents, methods of making and using same |
| AU725432B2 (en) * | 1996-04-17 | 2000-10-12 | Centaur Pharmaceuticals, Inc. | Nitrone free radical trap treatment of dementia associated with AIDS virus (HIV-1) infection |
| US6376540B1 (en) * | 1996-07-19 | 2002-04-23 | Centaur Pharmaceuticals, Inc. | Furan nitrone compounds |
| TW429241B (en) * | 1996-09-26 | 2001-04-11 | Sumitomo Pharma | Nitrone derivatives |
| US6046232A (en) * | 1997-10-17 | 2000-04-04 | Centaur Pharmaceuticals, Inc. | α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same |
| AU2226999A (en) * | 1998-01-16 | 1999-08-02 | Renovis, Inc. | Thiophene nitrone compounds |
| JP2002509143A (ja) * | 1998-01-16 | 2002-03-26 | センター ファーマシューティカルズ， インコーポレイテッド | チオエーテルフランニトロン化合物 |
| JP2002506022A (ja) * | 1998-03-13 | 2002-02-26 | センター ファーマシューティカルズ， インコーポレイテッド | 新脈管形成の阻害 |
| US6083989A (en) * | 1999-05-18 | 2000-07-04 | Centaur Pharmaceuticals, Inc. | Aryl nitrone therapeutics for the treatment of inflammatory bowel disease |
| AU3985799A (en) * | 1998-05-19 | 1999-12-06 | Centaur Pharmaceuticals, Inc. | Furan nitrone therapeutics for the treatment of inflammatory bowel disease |
| US6730700B2 (en) * | 1998-12-02 | 2004-05-04 | Renovis, Inc. | 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same |
| UA66401C2 (en) | 1998-12-02 | 2004-05-17 | Sentor Pharmaceuticals Inc | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same |
| ATE312103T1 (de) | 1999-01-25 | 2005-12-15 | Nat Jewish Med & Res Center | Substituierte porphyrine und deren therapeutische verwendungen |
| IL146143A0 (en) * | 1999-04-28 | 2002-07-25 | Univ Kingston | Compositions and methods for treating amyloidosis |
| BR9904931A (pt) * | 1999-10-18 | 2001-06-12 | Sergio Teixeira Ferreira | Inibição de amiloidoses |
| AU1574701A (en) * | 1999-10-22 | 2001-04-30 | Wrair Walter Reed Army Institute Of Research | A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| US6815425B1 (en) | 1999-10-22 | 2004-11-09 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| US20020022743A1 (en) * | 2000-01-10 | 2002-02-21 | Sergei Pouhov | Method for the purification of aryl sulfonic acids and salts |
| SE0000056D0 (sv) * | 2000-01-10 | 2000-01-10 | Astrazeneca Ab | Novel process |
| SE0000055D0 (sv) * | 2000-01-10 | 2000-01-10 | Centaur Pharmaceuticals Inc | Novel process |
| SE0001916D0 (sv) * | 2000-05-23 | 2000-05-23 | Astrazeneca Ab | Novel formulation |
| US6664297B1 (en) | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| AU2002253857A1 (en) | 2001-01-08 | 2002-09-04 | Centaur Pharmaceuticals, Inc. | Use of aryl nitrone compounds in methods for treating neuropathic pain |
| WO2003010154A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co. Ltd. | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses |
| US20030045461A1 (en) * | 2001-09-06 | 2003-03-06 | Jen-Chang Hsia | Composition and methods of esterified nitroxides gated with carboxylic acids |
| FR2846968B1 (fr) * | 2002-11-08 | 2005-02-04 | Salles Jean Pierre | Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20050059638A1 (en) * | 2003-08-04 | 2005-03-17 | Kelly Michael G. | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| US20050182060A1 (en) * | 2004-02-13 | 2005-08-18 | Kelly Michael G. | 2-Substituted and 4-substituted aryl nitrone compounds |
| EP1828111A2 (en) * | 2004-11-12 | 2007-09-05 | Neurochem (International) Limited | Methods and fluorinated compositions for treating amyloid-related diseases |
| CN101103018A (zh) * | 2004-11-16 | 2008-01-09 | 神经化学（国际）有限公司 | 治疗cns和淀粉样蛋白-相关疾病的化合物 |
| BRPI0519243A2 (pt) * | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide |
| US20060235370A1 (en) * | 2005-04-04 | 2006-10-19 | Oblong John E | Method of regulating mammalian keratinous tissue |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| WO2007013843A1 (en) * | 2005-07-26 | 2007-02-01 | Astrazeneca Ab | Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia |
| WO2007013842A1 (en) * | 2005-07-26 | 2007-02-01 | Astrazeneca Ab | Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain |
| WO2007013844A1 (en) * | 2005-07-26 | 2007-02-01 | Astrazeneca Ab | Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea |
| WO2007013841A1 (en) * | 2005-07-26 | 2007-02-01 | Astrazeneca Ab | Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema |
| MX2008008213A (es) * | 2005-12-22 | 2008-09-03 | Neurochem Int Ltd | Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias. |
| JP5236641B2 (ja) * | 2006-07-25 | 2013-07-17 | ハフ イヤ インスティテュート | 急性音響外傷の治療方法 |
| DK2089417T3 (en) | 2006-10-12 | 2015-03-23 | Bhi Ltd Partnership | Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid |
| CN101730529A (zh) * | 2006-12-22 | 2010-06-09 | 贝鲁斯健康(国际)有限公司 | 用于治疗代谢疾病和糖尿病的方法、化合物和组合物 |
| US20090082454A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched disufenton |
| US8425593B2 (en) | 2007-09-26 | 2013-04-23 | St. Jude Medical, Inc. | Collapsible prosthetic heart valves |
| WO2009102808A2 (en) | 2008-02-12 | 2009-08-20 | Tosk, Incorporated | Doxorubicin adjuvants to reduce toxicity and methods for using the same |
| CN102105146A (zh) | 2008-05-23 | 2011-06-22 | 国立犹太保健医院 | 用于治疗与暴露于烷化物质有关的损伤的方法 |
| AU2009288057B2 (en) | 2008-09-02 | 2014-07-03 | Oklahoma Medical Research Foundation | 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas |
| EP2470015B1 (en) * | 2009-08-24 | 2016-01-13 | Hough Ear Institute | Nitrone compounds for treating sensorineural hearing loss |
| ES2893825T3 (es) | 2011-02-04 | 2022-02-10 | Hough Ear Inst | Métodos de tratamiento de lesiones cerebrales |
| US10576125B2 (en) * | 2016-10-31 | 2020-03-03 | Hough Ear Institute | Methods for enhancing synaptogenesis and neuritogenesis |
| EP3570826A4 (en) | 2017-01-19 | 2020-09-23 | Otologic Pharmaceutics, Inc. | N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES |
| ES3063479T3 (en) * | 2017-09-20 | 2026-04-16 | Oklahoma Med Res Found | Treatment of drug resistant gliomas |
| US10829441B2 (en) | 2017-11-14 | 2020-11-10 | The University Of Toledo | Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke |
| EP3787750A1 (en) * | 2018-05-03 | 2021-03-10 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
| US12121501B2 (en) | 2018-09-12 | 2024-10-22 | Hough Ear Institute | Methods for treating hearing loss incident to cochlear implant surgery |
| KR20220145861A (ko) * | 2020-02-24 | 2022-10-31 | 오블라토 인코포레이티드 | 암 및 종양을 치료하기 위한 조성물 및 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3914650A1 (de) * | 1989-05-03 | 1990-11-08 | Basf Ag | Neue phenylendiamine sowie ein verfahren zur herstellung von phenylendiaminen |
| CA2069961C (en) * | 1989-10-17 | 2000-05-02 | John M. Carney | Method and compositions for inhibition of disorders associated with oxidative damage |
| US5025032A (en) * | 1989-10-17 | 1991-06-18 | Oklahoma Medical Research Foundation | Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage |
| US5036097A (en) * | 1989-10-17 | 1991-07-30 | Oklahoma Medical Research Foundation | Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration |
| DE3937342A1 (de) * | 1989-11-09 | 1991-05-16 | Bayer Ag | Verfahren zur herstellung von 2-aminobenzol-disulfonsaeuren-(1,4) und die neue verbindung 6-chlor-2-aminobenzol-disulfonsaeure-(1,4) |
| WO1992022290A1 (en) * | 1991-06-18 | 1992-12-23 | Oklahoma Medical Research Foundation | Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins |
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
-
1993
- 1993-12-23 US US08/173,579 patent/US5488145A/en not_active Expired - Lifetime
-
1994
- 1994-12-22 ES ES95907224T patent/ES2145264T3/es not_active Expired - Lifetime
- 1994-12-22 CZ CZ19961775A patent/CZ289629B6/cs not_active IP Right Cessation
- 1994-12-22 PL PL94315154A patent/PL185189B1/pl not_active IP Right Cessation
- 1994-12-22 NZ NZ279025A patent/NZ279025A/en unknown
- 1994-12-22 US US08/663,316 patent/US5780510A/en not_active Expired - Fee Related
- 1994-12-22 SK SK788-96A patent/SK282403B6/sk unknown
- 1994-12-22 CN CN94194993A patent/CN1070176C/zh not_active Expired - Fee Related
- 1994-12-22 JP JP51809895A patent/JP3412821B2/ja not_active Expired - Lifetime
- 1994-12-22 AU AU15527/95A patent/AU679835B2/en not_active Ceased
- 1994-12-22 KR KR1019960703367A patent/KR100370522B1/ko not_active Expired - Fee Related
- 1994-12-22 CA CA002179521A patent/CA2179521C/en not_active Expired - Lifetime
- 1994-12-22 DE DE69424441T patent/DE69424441T2/de not_active Expired - Fee Related
- 1994-12-22 DK DK95907224T patent/DK0736004T3/da active
- 1994-12-22 BR BR9408378A patent/BR9408378A/pt not_active Application Discontinuation
- 1994-12-22 AT AT95907224T patent/ATE192736T1/de not_active IP Right Cessation
- 1994-12-22 PT PT95907224T patent/PT736004E/pt unknown
- 1994-12-22 SG SG1996007103A patent/SG64903A1/en unknown
- 1994-12-22 EP EP95907224A patent/EP0736004B1/en not_active Expired - Lifetime
- 1994-12-22 WO PCT/US1994/014545 patent/WO1995017876A2/en not_active Ceased
- 1994-12-22 UA UA96072885A patent/UA45964C2/uk unknown
- 1994-12-22 RU RU96115200/04A patent/RU2159231C2/ru not_active IP Right Cessation
- 1994-12-22 HU HU9601739A patent/HU221167B1/hu not_active IP Right Cessation
-
1995
- 1995-01-27 TW TW084100747A patent/TW299315B/zh active
- 1995-04-24 US US08/426,961 patent/US5475032A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,564 patent/US5508305A/en not_active Expired - Lifetime
- 1995-06-20 MY MYPI95001668A patent/MY114178A/en unknown
- 1995-06-23 HR HR950358A patent/HRP950358B1/xx not_active IP Right Cessation
-
1996
- 1996-06-20 FI FI962589A patent/FI111718B/fi not_active IP Right Cessation
- 1996-06-20 NO NO962637A patent/NO306457B1/no unknown
-
1997
- 1997-05-13 BR BR1100626-9A patent/BR1100626A/pt active IP Right Grant
-
2000
- 2000-05-22 JP JP2000150128A patent/JP2001010953A/ja not_active Withdrawn
- 2000-08-07 GR GR20000401829T patent/GR3034134T3/el not_active IP Right Cessation
-
2003
- 2003-12-02 JP JP2003403744A patent/JP2004075696A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ289629B6 (cs) | 2,4-Disulfonyl-alfa-fenyl-terc.butylnitron, jeho soli, farmaceutická kompozice s jeho obsahem a pouľití | |
| US6355661B1 (en) | Methods for treatment of sickle cell anemia | |
| US20030022923A1 (en) | Methods for treatment of sickle cell anemia | |
| JP2007524683A (ja) | ２位置換および４位置換アリールニトロン化合物 | |
| ES2398339T3 (es) | 2,4-disulfonil fenil terc-butil nitrona para el tratamiento de gliomas | |
| US20100222376A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| JP2024099790A (ja) | 血管拡張剤およびその用途 | |
| JP2009535410A (ja) | ピロロキノリンキノンおよびその使用 | |
| JP2000509375A (ja) | 眼炎症の処置における使用のためのニトロン化合物を含む組成物 | |
| TW200301100A (en) | Treatment of neurodegenerative and cardiovascular disorders | |
| HK1008294B (en) | (2-4-disulfophenyl) n-tertiary butyl nitrone its salts, and their use as pharmaceutical radical trapping agents | |
| JPH06509556A (ja) | エタノール摂取を妨げるチオカルバメートスルホキシド組成物 | |
| KR20230152480A (ko) | 췌장암 또는 유방암의 예방 또는 치료용 약제학적 조성물 | |
| AU672364B2 (en) | Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins | |
| BR112023010742B1 (pt) | Uso de derivados de mononucleotídeo de nicotinamida e da composição farmacêutica que os compreende | |
| JPS59196818A (ja) | 腎炎治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20061222 |